We found that inhibition of AKT-signaling in GIST and STS cell lines results in a significantly decreased expression of Rad51 recombinase and number of residual Rad51/BRCA1 foci in Dox-treated tumor cells. The gene discussed is AKT1; the disease is neoplasm.